5 Analysts Have This to Say About Krystal Biotech
Portfolio Pulse from Benzinga Insights
Five analysts have given bullish ratings for Krystal Biotech (NASDAQ:KRYS) in the last quarter, with an average price target of $149.0, implying an upside from the current price of $114.03. The average price target has increased by 0.68% over the past month.
October 12, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given bullish ratings for Krystal Biotech, implying a potential upside.
The bullish ratings from five analysts indicate a positive sentiment towards Krystal Biotech. This, combined with the average price target that is higher than the current price, suggests a potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100